Retinal Research Institute – Phoenix
Retinal Consultants of Arizona has a strong commitment to medical research and the advancement of treatments for retinal diseases. Unfortunately, there are many medical conditions that do not have a “cure.” Although we provide the latest technology available to treat retinal disorders, we are actively involved in multiple clinical research trials in hopes of expanding our treatment options for our patients. RCA physicians contribute to the advancement of new therapies by participating in clinical research studies.
We have been participating in clinical trials since 1998 and are proud that the Retinal Research Institute has become one of the nation’s largest retina & vitreous-specific research organizations. In many instances, RCA is the only retina group in Arizona to offer patient participation in multiple studies addressing multiple eye conditions
Mission / Purpose
Retinal Consultants of Arizona’s mission is to provide the most up to date and effective treatments for patients with retinal diseases.
News
Keep up with new research and findings from recent studies and trials.
Current Studies & Trials
Find out what current studies and trials we are enrolling for.
Interested in a Clinical Trial?
If you or someone you know is interested in more information about our clinical research trials, please contact us.
(602) 222-2221
Follow Us On Social
Pravin U. Dugel MD: Economic Value of Anti–Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States
/ Uncategorized /by retinalconsultantsKaren Mulligan, PhD1,6; Seth A. Seabury, PhD2,6; Pravin U. Dugel, MD3,4; et al Key Points Question How much economic value do anti–vascular endothelial growth factor (anti-VEGF) treatments generate for patients with wet age-related macular degeneration and society in the United States? Findings In this economic evaluation study, visual acuity improvement associated with anti-VEGF treatments generated $5.1 billion to $8.2 billion in […]
Pravin U. Dugel, MD: Conversations in Age-Related Macular Degeneration
/ Uncategorized /by retinalconsultantsNeovascular AMD Pravin U. Dugel, MD What up-and-coming therapies for wet AMD are you most excited about and why? The therapies currently being investigated for neovascular age-related macular degeneration (nvAMD) can be stratified into 3 silos: better short-term efficacy, better long-term efficacy, and increased durability. The majority of drugs in the pipeline have focused on […]